在长期幸存的小细胞肺癌复发患者中,第二次免疫治疗的持续反应
Natalie Shammas1, Sajjad Bhatti2
1Internal Medicine, CHI Saint Vincent Health System, Little Rock, Arkansas, USA.
BMJ case reports
|August 25, 2025
概括
在扩散性小细胞肺癌 (ES-SCLC) 患者中,长期存活是可能的. 停用维持免疫治疗后的复发可以通过第二次免疫治疗有效治疗,从而实现持久的缓解.
科学领域:
- 癌症学
- 免疫疗法
- 小细胞肺癌
背景情况:
- 化学免疫治疗 (CIT) 改善了扩散阶段小细胞肺癌 (ES-SCLC) 的结果.
- 在ES-SCLC患者中复发是常见的,即使在初始治疗成功后.
- 维持免疫治疗的最佳持续时间和复发后的再治疗选择尚未明确.
研究的目的:
- 展示ES-SCLC的长期存活情况.
- 探索在停止维持免疫治疗后复发的患者的治疗选择.
- 评估复发性ES-SCLC的第二次免疫治疗疗程的疗效.
主要方法:
- 一个ES-SCLC患者的病例报告实现了长期存活.
- 患者在2年后停止了化疗免疫治疗.
- 患者出现了疾病复发,并重新接受单剂免疫疗法.
主要成果:
- 患者在第二次免疫治疗后实现了持久缓解.
- 这表明,在复发后,免疫疗法可能有潜在的疗效.
- 突出了ES-SCLC的长期生存和再治疗选择的可能性.
结论:
- 维持免疫治疗的持续时间需要进一步调查.
- 在复发的ES-SCLC患者中,免疫疗法可作为可行的选择.
- 这一案例突显了ES-SCLC在免疫治疗中长期缓解的潜力.
更多相关视频
10:29Semi-automatic PD-L1 Characterization and Enumeration of Circulating Tumor Cells from Non-small Cell Lung Cancer Patients by Immunofluorescence
Published on: August 14, 2019
10.7K
09:56A Nonviral Approach to Generate Transient Chimeric Antigen Receptor T Cells Using mRNA for Cancer Immunotherapy
Published on: February 21, 2025
791
相关概念视频
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
Tumor Immunotherapy
660
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
660
Cells of the Adaptive Immune Response
4.0K
The T and B lymphocytes of the adaptive immune system develop from common lymphoid progenitor cells in the bone marrow. These progenitors give rise to precursors that eventually develop into both T and B lymphocytes. As these precursors mature, they gain the ability to detect and respond to foreign antigens in the body, a process known as immunocompetence. Additionally, these precursors acquire self-tolerance, a process that ensures they do not react to self-antigens. This intricate system...
4.0K
